0 -0.000475914583678237 -0.000475914583678237 -0.000600066214202989 -0.000620758152623761 -0.00469831153782487 -0.00312448270153958 -0.0082767753683165
Sign Up Today X
Thanks for submitting the form.
Stockreport

Physician-Scientist Reshma Kewalramani Runs One of Biotech's Biggest Companies [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Reshma Kewalramani Credit - Erin Clark—The Boston Globe/Getty Images A clear thread runs through Reshma Kewalramani's career, connecting her start as a kidney doctor, her years leading drug research and development at Amgen, and her present role as CEO and president of Vertex Pharmaceuticals . “What I wanted to do was make medicines for patients,” she says. Kewalramani took the helm of Vertex in 2020, a move that made her the first female CEO of a large, public biotechnology company. Under her leadership , Vertex in late 2023 launched the first CRISPR-based gene-editing therapy—a treatment for sickle-cell disease—and a new class of FDA-approved nonopioid pain medication in January 2025. The company has also continued to deliver breakthrough drugs for cystic fibrosis . “When I was in medical school, the average age of death [for patients with cystic fibrosis] was 27,” she says. Today, models suggest an average patient who starts medication in their youth will live beyond 70. But [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

Physician-Scientist Reshma Kewalramani Runs One of Biotech's Biggest Companies [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Reshma Kewalramani Credit - Erin Clark—The Boston Globe/Getty Images A clear thread runs through Reshma Kewalramani's career, connecting her start as a kidney doctor, her years leading drug research and development at Amgen, and her present role as CEO and president of Vertex Pharmaceuticals . “What I wanted to do was make medicines for patients,” she says. Kewalramani took the helm of Vertex in 2020, a move that made her the first female CEO of a large, public biotechnology company. Under her leadership , Vertex in late 2023 launched the first CRISPR-based gene-editing therapy—a treatment for sickle-cell disease—and a new class of FDA-approved nonopioid pain medication in January 2025. The company has also continued to deliver breakthrough drugs for cystic fibrosis . “When I was in medical school, the average age of death [for patients with cystic fibrosis] was 27,” she says. Today, models suggest an average patient who starts medication in their youth will live beyond 70. But [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS